Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2018-06-14 Share Issue/Capital Cha…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of May 31, 2018. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory filing requirement in France, often related to changes in major shareholdings or capital structure transparency. While it touches upon capital structure, the primary focus is the monthly disclosure of voting rights and shares. This aligns best with the 'Major Shareholding Notification' (MRQ) category, which covers changes in significant share ownership levels, or potentially a general 'Regulatory Filing' (RNS) if MRQ is too specific for a routine monthly update not triggered by a threshold breach. However, given the explicit focus on the total number of voting rights and shares, which is a key component of major shareholding disclosures, MRQ is the most appropriate fit among the provided options, as it relates directly to the composition of ownership/voting power.
2018-06-14 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release titled "NANOBIOTIX' MANAGEMENT STATEMENT ON RECENT SHARE PRICE VARIATION." It addresses market concerns regarding share price movement and confirms that no undisclosed material news has occurred. It also provides an update on an expected data release timeline. This type of communication, which addresses market rumors or provides brief, non-periodic operational updates outside of formal financial reports (like 10-K or IR), typically falls under general regulatory announcements or investor relations communications. Since it is not a formal Earnings Release (ER), Interim Report (IR), or a specific transaction report (like DIRS or POS), and it is a direct communication to the market regarding company status, it best fits the Regulatory Filings (RNS) category as a general regulatory announcement/press release, or potentially a communication related to investor relations that doesn't fit a more specific category. Given the context of addressing share price volatility and confirming operational status, RNS is the most appropriate general classification for this type of market statement.
2018-06-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "NANOBIOTIX : DECLARATION A LA SUITE DE LA VARIATION RECENTE DU PRIX DE L'ACTION" (Declaration following the recent variation in the stock price). It explicitly states that the company observed a significant drop in its stock price and confirms that no new information or particular event has occurred, addressing market concerns. This type of communication, often issued in response to unusual stock price movements without a corresponding formal filing event (like earnings or a major corporate action), is typically classified as a general regulatory announcement or a specific market disclosure. Since it is not a formal financial report (10-K, IR, ER), a management change (MANG), or a director's dealing (DIRS), it fits best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a mandatory disclosure to maintain market transparency regarding stock price volatility.
2018-06-06 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of April 30, 2018. This content directly relates to changes in share capital structure and voting rights reporting, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it reports the current state of the capital base and voting rights, often required following capital movements or as a routine disclosure related to capital structure. While it touches upon voting rights, it is a report on the capital structure itself, not the results of a vote (DVA). Given the focus on the total number of shares and voting rights, SHA is the most appropriate classification.
2018-05-04 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 95% confidence The document is a press release dated May 3, 2018, announcing a research collaboration between NANOBIOTIX and Weill Cornell Medicine regarding the NBTXR3 product. It details scientific objectives, quotes researchers, mentions ongoing and planned clinical trials (FDA approval for a study starting Q2 2018), and provides company background and contact information. This format—a news announcement about business/scientific developments, often including forward-looking statements and contact details—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a voting result (DVA), and it is a primary announcement of business news, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's just a general corporate update. Given the content is a specific partnership announcement rather than a summary of financial performance, RNS is a strong candidate. However, press releases announcing significant operational updates, especially those mentioning clinical trial progress and future plans, are often categorized broadly. Since there is no specific category for 'Partnership Announcement' and it is not a short announcement pointing to a separate report (RPA), RNS is the most appropriate fallback for a significant, non-financial-summary corporate announcement.
2018-05-03 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated May 3, 2018, announcing a research collaboration between Nanobiotix and Weill Cornell Medicine regarding the NBTXR3 product. It details scientific objectives, quotes researchers, mentions ongoing and planned clinical trials (FDA authorization for an anti-PD1 combination trial starting Q2 2018), and provides company background and contact information. This format—a formal announcement of a business/research development, often containing forward-looking statements and regulatory context (like FDA/AMF filings mentioned in the disclaimer)—is characteristic of a general corporate press release. Since it is not a full financial report (10-K, IR), a specific financial event (CAP, DIV), or a transcript (CT), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it serves as a public disclosure of material, non-financial operational news.
2018-05-03 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.